IFB research group takes part in CELONKO project on development of novel anti-cancer drugIFB research group takes part in CELONKO project on development of novel anti-cancer drug

The aim of CELONKO project is preclinical and clinical development of novel anti-cancer drug targeting FGR receptors. Scientists in the Laboratory of Molecular Enzymology IFB in cooperation  with researchers in the Department of Histology FM are about to start studies on a potent, low molecular-weight FGF-R inhibitor characterized by an appropriate specificity and pharmacokinetic properties in treatment of squamous lung, stomach and bladder FGF-R driven cancers. The above units belonging to the Gdansk University of Medicine are part of Consortium also consisting of: Celon Pharma S.A. (leader), National Institute of Tuberculosis and Lung Disease, Military Institute of Medicine, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology.

Besides the feasibility studies on the potential drug, the second aim of CELONKO project is to develop a diagnostic test to identify patients with FGF-R aberrations, and to identify novel biomarkers of such genetic alterations. Until now, no selective inhibitor targeting tyrosine protein kinases in FGF receptors has been approved for treatment of disease. This innovative investigational compound is foreseen to have a broad therapeutic spectrum and limited side effects what promises a truly innovative solution in treatment of genetically well-defined group of cancers.